BridgeBio (BBIO) Soars 13% on Double-Digit Price Target Upgrade
In a market report, JPMorgan raised its price target for BridgeBio Pharma Inc. (NASDAQ:BBIO) to $94 from $89 previously, marking a 26 percent upside potential from its latest closing price.






